Ionis Pharmaceuticals Inc $ 57.48 -1.76 (-2.97%)
Volume:
1,336,087
Avg Vol (1m):
742,286
Market Cap $:
8.01 Bil
Enterprise Value $:
6.63 Bil
P/E (TTM):
52.24
P/B:
5.88
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.99 | ||
| Equity-to-Asset | 0.44 | ||
| Debt-to-Equity | 0.59 | ||
| Debt-to-EBITDA | 3.51 | ||
| Interest Coverage | 3.8 | ||
| Piotroski F-Score | 7 | ||
| Altman Z-Score | 4.3 | ||
| Beneish M-Score | -2.42 | ||
| WACC vs ROIC | |||
Profitability Rank | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 19.11 | ||
| Net Margin % | 16.84 | ||
| ROE % | 12.33 | ||
| ROA % | 5.41 | ||
| ROC (Joel Greenblatt) % | 143.68 | ||
| 3-Year Revenue Growth Rate | 36.6 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 52.24 | ||
| PE Ratio without NRI | 52.24 | ||
| Price-to-Owner-Earnings | 624.78 | ||
| PB Ratio | 5.88 | ||
| PS Ratio | 8.51 | ||
| Price-to-Free-Cash-Flow | 43.86 | ||
| Price-to-Operating-Cash-Flow | 35.77 | ||
| EV-to-EBIT | 31.4 | ||
| EV-to-EBITDA | 29.18 | ||
| EV-to-Revenue | 6.9 | ||
| Current Ratio | 9.91 | ||
| Quick Ratio | 9.83 | ||
| Days Inventory | 13.63 | ||
| Days Payable | 16.03 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.01 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 2.37 | ||
| Price-to-Median-PS-Value | 0.67 | ||
| Price-to-Graham-Number | 3.73 | ||
| Earnings Yield (Greenblatt) % | 3.17 |